Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Discussion Abstracts

Abstract PD3-3: Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer

RD Iggo, HM Wood, P Rabbitts, N Quenel-Tueux, L Mauriac, G MacGrogan, H Bonnefoi and HORGEN Investigators
RD Iggo
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HM Wood
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Rabbitts
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Quenel-Tueux
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L Mauriac
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G MacGrogan
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H Bonnefoi
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
DOI: 10.1158/0008-5472.SABCS13-PD3-3 Published December 2013
  • Article
  • Info & Metrics
Loading

Article Information

Volume 73, Issue 24 Supplement, pp. PD3-3

DOI 
https://doi.org/10.1158/0008-5472.SABCS13-PD3-3

Published By 
American Association for Cancer Research
Print ISSN 
0008-5472
Online ISSN 
1538-7445


Author Information

  1. RD Iggo,
  2. HM Wood,
  3. P Rabbitts,
  4. N Quenel-Tueux,
  5. L Mauriac,
  6. G MacGrogan,
  7. H Bonnefoi,
  8. HORGEN Investigators
  1. INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom

Previous
Back to top
Cancer Research: 73 (24 Supplement)
December 2013
Volume 73, Issue 24 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract PD3-3: Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract PD3-3: Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer
RD Iggo, HM Wood, P Rabbitts, N Quenel-Tueux, L Mauriac, G MacGrogan, H Bonnefoi and HORGEN Investigators
Cancer Res December 15 2013 (73) (24 Supplement) PD3-3; DOI: 10.1158/0008-5472.SABCS13-PD3-3

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract PD3-3: Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer
RD Iggo, HM Wood, P Rabbitts, N Quenel-Tueux, L Mauriac, G MacGrogan, H Bonnefoi and HORGEN Investigators
Cancer Res December 15 2013 (73) (24 Supplement) PD3-3; DOI: 10.1158/0008-5472.SABCS13-PD3-3
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Discussion Abstracts

  • Abstract PD1-11: Moderate risk genes matter: Multigene testing for hereditary breast cancer
  • Abstract PD2-01: Ultrasound together with clinical indexes cannot predict sentinel lymph node metastasis for ultrasound-axillary lymph node-negative breast cancer patients
  • Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
Show more 3

Poster Discussion 3: Endocrine Resistance

  • Abstract PD3-8: Whole exome sequencing reveals early mutational change on endocrine and targeted therapy in estrogen receptor (ER)-positive breast cancer
  • Abstract PD3-4: A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
  • Abstract PD3-7: Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement